McKesson Canada
33 meetings with public office holders, Jun 5, 2025 to Jul 29, 2026.
130 meetings on record since the registry opened in 2008.
Meetings over time
- Jun 2025: 2 meetings, with Sean Burgess, Neerja Bhalla
- Jul 2025: 9 meetings, with Guillaume Couillard, Anie Perrault, Sandenga Yeba, Chris Malette, Neeraj Bhalla
- Aug 2025: 5 meetings, with Sandenga Yeba, Sendenga Yeba, Yves-Joseph Rosalbert, Marjorie Michel, Ernie Klassen
- Sep 2025: 0 meetings
- Oct 2025: 1 meeting, with Kristina Tesser-Derksen
- Nov 2025: 0 meetings
- Dec 2025: 0 meetings
- Jan 2026: 3 meetings, with Maggie Chi, Maninder Sidhu, Rechie Valdez
- Feb 2026: 1 meeting, with Pamela Aung-Thin
- Mar 2026: 0 meetings
- Apr 2026: 11 meetings, with Anthony Laporte, Jade Mallette, Shalene Curtis-Micallef, Paul Morin, Manuela Tomic
- May 2026: 0 meetings
- Jun 2026: 0 meetings
- Jul 2026: 1 meeting, with Rechie Valdez
Jun 2025peak 11 in a monthJul 2026
Hover or focus a month to see who was met.
What they lobby about
- Health33
- Industry28
- Foreign Affairs18
- Transportation18
- Economic Development12
- Internal Trade10
- International Relations10
- International Trade10
- Federal-Provincial Relations1
The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.
Who they met
Liberal7 met · 9 meetings
Not in Arena's member list21 met · 30 meetings
- Sandenga Yeba
- Anthony Laporte
- Galen Richardson
- Jade Mallette
- Shalene Curtis-Micallef
- Yves-Joseph Rosalbert
- Aaron Wudrick
- Ali Ehsaasi
- Anie Perrault
- Bryn Savage
- Elizabeth Wong
- Guillaume Couillard
- Jibril Hussein
- Mackenzy Metcalfe
- Manuela Tomic
- Neeraj Bhalla
- Neerja Bhalla
- Pamela Aung-Thin
- Paul Morin
- Sean Burgess
- Sendenga Yeba
Health Canada (HC) (17) · House of Commons (8) · Innovation, Science and Economic Development Canada (ISED) (3) · Global Affairs Canada (GAC) (3) · Prime Minister's Office (PMO) (2) · Patented Medicine Prices Review Board (PMPRB) (2)
In their own words
- Offer recommendations on the Patented Medicines Pricing Review Board excessive pricing policy guidelines and implementation approaches to support drug supply stability and system sustainability
- Policies and programs aimed at red tape reduction to reduce regulatory burdens and timelines in the pharmaceutical distribution and associated sectors
- Health Canada, with respect to the regulation and funding of wholesale distribution of pharmaceuticals and regulation of pharmacy activities
Meetings from the Commissioner of Lobbying of Canada. Canada does not require lobbyists to disclose what they spend, so there is no lobbying budget to report here — only the meetings they filed.